Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Alveoli and Alveolar Ducts

Alveoli and Alveolar Ducts

The respiratory zone of the human body, which stands in contrast to the conducting zone, comprises the structures that actively participate in the exchange of gases. The initiation of this zone is marked by the terminal bronchioles converging into respiratory bronchioles, the tiniest bronchiole classification. The respiratory bronchioles give way to the alveolar ducts that opens into a congregation of alveoli. Actively involved in gas exchange, alveoli resemble tiny sacs similar to clusters of...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Atelectasis II: Pathophysiology

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel CAF-identifiers via transcriptomic and protein level analysis in HNSC patients.

Scientific reports·2023

Same author

Pregnancy in a Rare Case of Intracranial Rosai Dorfman Disease (RDD).

Journal of obstetrics and gynaecology of India·2020

Same author

Hypersensitivity pneumonitis: Clinical manifestations - Prospective data from the interstitial lung disease-India registry.

Lung India : official organ of Indian Chest Society·2019

Same author

Interstitial Lung Disease in India. Results of a Prospective Registry.

American journal of respiratory and critical care medicine·2016

Same author

Pulmonary mucormycosis presenting with vocal cord paralysis.

Respiratory medicine case reports·2015

Same author

Left hepatic lobe herniation through an incisional anterior abdominal wall hernia.

The Indian journal of medical research·2015

Search research articles

Related Experiment Video

Updated: May 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Pulmonary alveolar microlithiasis.

H J Gayathri Devi¹, K N Mohan Rao, K M Prathima

¹Department of Chest Diseases, MS Ramaiah Medical College, Bangalore, India.

Lung India : Official Organ of Indian Chest Society

|June 30, 2011

Summary

This summary is machine-generated.

Pulmonary alveolar microlithiasis, a rare lung disease, was diagnosed in a young boy. His condition presented as failure to thrive and miliary mottling on chest X-ray, confirmed by lung biopsy.

Keywords:

Pulmonary alveolar microlithiasis biopsy miliary tuberculosis misdiagnosis

More Related Videos

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Related Experiment Videos

Last Updated: May 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Area of Science:

Pulmonology
Rare Diseases
Pediatric Medicine

Background:

Pulmonary alveolar microlithiasis (PAM) is an uncommon interstitial lung disease.
The etiology of PAM remains largely unknown.
Diagnosis often relies on characteristic radiographic findings and histological confirmation.

Purpose of the Study:

To report a case of pulmonary alveolar microlithiasis in a pediatric patient.
To highlight the diagnostic challenges and presentation of this rare condition.

Main Methods:

Case report of a young male patient.
Clinical presentation including failure to thrive.
Imaging studies: chest X-ray demonstrating miliary mottling.
Histopathological examination: open lung biopsy.

Main Results:

The patient exhibited failure to thrive and radiographic evidence of miliary mottling.
Open lung biopsy confirmed the diagnosis of pulmonary alveolar microlithiasis.
This case underscores the presentation of PAM in a pediatric demographic.

Conclusions:

Pulmonary alveolar microlithiasis can present insidiously in children with non-specific symptoms.
Early diagnosis through imaging and biopsy is crucial for managing this rare lung condition.
Further research into the pathogenesis of PAM is warranted.